Scholars Central

Research articlePublished 3 Mar 2022

A Dialectological Pharmacovigilance Study of the Rational Pharmacotherapeutic Appraisal of the Combination Therapies of 50 mg or 75 mg Remogliflozin with 500 mg Metformin, and an Anti-Diabetic Tertiary Medical Healthcare Patient Satisfaction Evaluation: A Research Series, in Evidence-Based Medicine

Authors: Moumita Hazra

Journal of Evidence-Based Medicine and Healthcare

Volume 9 · Issue 4 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

INTRODUCTION Remogliflozin, a selective insulin independent sodium glucose co - transporter subtype 2 (SGLT2) inhibitor, inhibits reabsorption of renal glucose, lowers blood sugar, and causes glucosuria, in type II diabetes mellitus patients. Metformin, as a combination anti-diabetic drug, lowers serum glucose levels; by the activation of 5’ Adenosine Monophosphate (AMP) activated protein kinase. OBJECTIVES The objective of this Evidence-Based Medicine research series was the rational pharmacotherapeutic appraisal of the diabetological pharmacovigilance of the combination therapies of 50 mg or 75 mg remogliflozin with 500 mg metformin among type II diabetics, in tertiary care medical college hospitals, along global pharmacoepidemiology, and an anti - diabetic tertiary medical healthcare patient satisfaction evaluation. METHODS 125 new early moderate grade type II diabetes mellitus patients were prescribed oral metformin 500 mg once daily for 30 days. Then, 100 diabetics uncontrolled with metformin monotherapy, were prescribed oral 50 mg remogliflozin with 500 mg metformin once daily, for 15 days; who were subsequently prescribed oral 75 mg remogliflozin with 500 mg metformin once daily for 15 days. The safety assessment, along with blood sugar and HbA1c levels and urine routine examination, on day 0, day 30, day 46, day 60, and further follow - up, were recorded and statistically analysed. An anti - diabetic tertiary medical healthcare patient satisfaction evaluation was also performed by patient response to different attributes of anti-diabetic treatment. RESULTS The adverse effects with the combination therapy of 50 mg remogliflozin with metformin and the combination therapy of 75 mg remogliflozin with metformin were statistically non - significant; hence both were safe and tolerable. All the patients were satisfied with each anti-diabetic medical healthcare attribute. CONCLUSION The combination therapy of 50 mg remogliflozin and metformin as well as the combination therapy of 75 mg remogliflozin and metformin were safe and tolerable. There was ample anti - diabetic medical healthcare satisfaction.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Evidence-Based Medicine and Healthcare.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Evidence-Based Medicine and Healthcare
  • SubjectNursing & Healthcare
  • BylineArticles whose byline prints “Moumita Hazra”